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Immune reconstitution disease (IRD), also 
referred to as ‘immune reconstitution inflam-
matory syndrome’ or ‘immune restoration dis-
ease’, is a widely recognized phenomenon that 
may complicate antiretroviral therapy (ART) 
[1,2]. This occurs most commonly, although not 
exclusively, in those with opportunistic infec-
tions (OIs) and results from rapid restoration 
of pathogen-specific immune responses. IRD 
may occur in two different scenarios (Figure 1). 
The ‘paradoxical’ form of IRD occurs when 
an OI diagnosed pre-ART initially responds 
successfully to treatment but then deteriorates 
as a direct result of immune recovery follow-
ing ART initiation. By contrast, the ‘unmask-
ing’ form of IRD occurs when an OI present 
pre-ART remains undiagnosed and subsequent 
immune recovery following ART initiation trig-
gers the presentation of OI with the development 
of unusual inflammatory features. 
IRD is recognized to be associated with 
a wide spectrum of pathogens and typically 
occurs during the initial months of ART when 
the prevalence of OIs is highest and immune 
recovery is most rapid. The opportunistic dis-
eases most commonly associated with IRD 
include mycobacterial diseases, including TB, 
Mycobacterium avium complex disease, leprosy 
and a wide range of other nontuberculous myco-
bacterial diseases; deep fungal infections, espe-
cially cryptococcal meningitis; herpes viruses, 
including cytomegalovirus (CMV) retinitis, 
 herpes zoster and herpes simplex; Kaposi’s sar-
coma (KS) and progressive multifocal leukoen-
cephalopathy (PML). The diverse clinical mani-
festations and clinical sequelae of IRD have been 
well documented [1–10]. 
A systematic review and meta-ana lysis of data 
from 54 cohorts containing over 13,000 patients 
provided summary estimates of the frequency of 
some of the most common forms of paradoxical 
IRD and the associated mortality risk (Table 1). 
CMV retinitis was complicated by IRD in over 
one third of cases [11]. Paradoxical IRD occurred 
in one in five patients with cryptococcal men-
ingitis and one in six patients with TB. Both 
cryptococcal IRD and TB-IRD were associated 
with mortality risk, although this was substan-
tially greater for those with cryptococcal disease 
(20.8 vs 3.2%, respectively) (Table 1). Although 
IRD associated with M. avium complex was 
one of the most commonly recognized forms 
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of IRD following the advent of ART in high-income countries 
[12], risk has subsequently diminished with initiation of ART at 
higher CD4+ cell counts. Moreover, with scale-up in resource-
limited settings, TB-IRD has become the predominant form of 
 mycobacterial IRD [13]. 
In contrast to paradoxical forms of TB and cryptococcal 
IRD, the frequencies of unmasking forms of IRD and associ-
ated mortality remain poorly defined. This is largely because 
of the widely acknowledged limitations in case definitions for 
unmasking disease [4,6]. Cases of TB and cryptococcal menin-
gitis presenting during the initial months of ART may arise 
either as a result of unmasking of subclinical prevalent dis-
ease or may be due to development of new incident disease 
in the context of persisting immunodeficiency. Clinical case 
definitions are largely unable to resolve these two etiologies in 
 individual patients. 
For many patients, IRD presents as a 
self-limiting complication with few conse-
quences. For some, however, there may be 
considerable morbidity, requiring hospital-
ization, therapeutic procedures or immuno-
suppressive therapy. IRD can also lead to 
diagnostic uncertainty, considerably com-
plicating clinical management. The poten-
tial complications of IRD are diverse, but 
include visual loss due to CMV-associated 
immune recovery uveitis; abscess formation 
within lymph nodes, soft tissues or solid 
organs due to TB-IRD; airway obstruction 
in those with nontuberculous mycobacteria, 
TB-IRD or KS-IRD; and respiratory fail-
ure and hepatic dysfunction in those with 
TB-IRD. In addition, manifestations may 
be life threatening, especially with IRD 
involving the CNS such as in those with tuberculous meningitis, 
cryptococcal meningitis or PML [9,10]. Overall, the two most impor-
tant forms of IRD are paradoxical TB-IRD (owing to associated 
morbidity) and unmasking and paradoxical forms of cryptococcal 
IRD (owing to associated mortality). 
Thus, IRD remains an important clinical problem and strate-
gies for prevention are needed. In this article we first summarize 
what is known about the risk factors and immunopathogenesis 
of IRD. We then use these data to describe the rationale for 
known and potential interventions that might be implemented 
at  programmatic and clinical levels for prevention.
Risk factors
Risk of unmasking IRD is directly related to the prevalence of 
undiagnosed OIs at baseline, which in turn will be related to the 
degree of immunodeficiency of patients, the methods used to 
screen for OIs and the prevailing frequency 
of specific OIs in the geographic location. 
Additional key risk factors associated with 
paradoxical IRD (some of which may also 
contribute to unmasking IRD risk) include 
the timing of ART during OI treatment, 
extent of the OI, baseline CD4 count and 
HIV viral load, and response of CD4 count 
and HIV viral load to ART. Each of these is 
considered in the following sections.
Timing of antiretroviral therapy
The residual amount of OI antigen present 
in the body tissues when ART is initiated is 
likely to be a key factor associated with risk of 
IRD. This, in turn, relates to the duration of 
effective treatment for the OI prior to ART. 
Many observational studies of TB [14–17] have 
found an association between earlier ART 
initiation during TB treatment and higher 
risk of paradoxical IRD. In a report from a 
Table 1. Results of a systematic review and meta-analysis of the 
incidence of immune reconstitution disease and resulting mortality 
associated with a range of opportunistic infections.
Opportunistic infection Pooled summary incidence, 
% (95% CI)
Proportion dying, 
% (95% CI)
Unselected patients starting ART
Any type of IRD 16.1 (11.1–22.9) 4.5 (2.1–8.6)
Patients with previous AIDS-defining illness
TB 15.7 (9.7–24.5) 3.2 (0.7–9.2)
Cryptococcal meningitis 19.5 (6.7–44.8) 20.8 (5.0–52.7)
Cytomegalovirus retinitis 37.7 (26.6–49.4)
Herpes zoster 12.2 (6.8–19.6)
Kaposi’s sarcoma 6.4 (1.2–24.7)
Progressive multifocal 
leukoencephalopathy 
16.7 (2.3–50.7)
ART: Antiretroviral therapy; IRD: Immune reconstitution disease. 
Data taken from [11].
OI diagnosed and 
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before ART initiation
Clinical deterioration of OI
as a result of ART-induced
immune recovery
= Paradoxical IRD
Atypical inflammatory 
presentation of OI as a
result of ART-induced 
immune recovery
= Unmasking IRD
No OI diagnosis
before ART initiation
ART 
initiation
Figure 1. ‘Unmasking’ and ‘paradoxical’ forms of immune reconstitution disease 
associated with opportunistic infections during early antiretroviral therapy.  
ART: Antiretroviral therapy; IRD: Immune reconstitution disease;  
OI: Opportunistic infection.
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South African cohort, the very strong rela-
tionship between duration of TB treatment 
prior to ART and risk of IRD (Figure 2) per-
sisted in adjusted analyses [15]. Risk appears 
to be particularly heightened when starting 
ART during the first 2 months of TB treat-
ment and this has recently been confirmed 
in randomized strategy trials of the optimum 
timing of ART during TB treatment [18,19]. 
The impact of the timing of ART on risk of 
cryptococcal IRD is unclear and the literature 
is complicated in some retrospective studies 
by concurrent reporting of both unmasking 
and paradoxical forms of the disease [20,21]. 
Higher risk of cryptococcal IRD in patients 
receiving earlier ART observed in some retro-
spective studies [20,21] is not supported by the 
findings of other studies [22,23]. 
Extent of opportunistic infection
Patients with evidence of more extensive or 
disseminated OIs appear to be at increased 
risk of IRD, which is likely to be related 
to a greater antigen burden. Patients with 
advanced immunosuppression whose 
immune systems are poorly able to control microbial replication 
prior to initiating appropriate antimicrobial therapy are therefore 
at greater risk of IRD. 
Risk of paradoxical TB-IRD is increased in those with extra-
pulmonary [16,24,25] or disseminated TB [26,27] and was positively 
correlated with mycobacterial antigen load in a rabbit model of 
TB-IRD [28]. Although the burden of Mycobacterium tuberculosis 
in humans cannot be directly measured, the major cell wall 
antigen lipoarabinomannan (LAM) is detectable in the urine 
of HIV-infected TB patients with advanced immunodeficiency 
and especially in those with disseminated TB [29,30]. LAM detec-
tion may therefore serve as a useful index of systemic antigen 
burden. Among 22 patients who were at risk for paradoxical 
TB-IRD when starting ART in a South African study, a positive 
urinary LAM assay at baseline was observed in all five patients 
who developed TB-IRD and in only one of 17 patients who did 
not [29]. Thus, urine LAM may be a useful predictive marker of 
those at highest risk of TB-IRD.
In studies of patients with cryptococcal meningitis, risk of 
IRD was associated with positive blood cultures [21] and higher 
cerebro spinal fluid (CSF) [20] and serum [23] cryptococcal antigen 
titer at diagnosis. Similarly, risk of IRD associated with KS was 
associated with detectable KS-associated herpesvirus [31]. IRD 
associated with CMV retinitis was positively associated with the 
clinical extent of disease [32]. 
Baseline CD4 count & HIV viral load & changes on ART
In a large meta-ana lysis, higher risk of paradoxical IRD was 
observed among those with lower baseline CD4 cell counts, espe-
cially those with counts <50 cells/µl [11]. This may potentially 
reflect an increased risk of high OI antigen burden, greater poten-
tial for rapid improvements in immune function or an increased 
risk of dysregulated immune recovery.
In studies of IRD associated with TB or cryptococcal meningi-
tis, greater risk was not only observed in those with lower baseline 
CD4 cell counts [15,21,27] but also in those with the greatest incre-
ments during ART in CD4 cell count [22,27], CD4 cell count per-
centage and CD4/CD8 ratio [26]. Other studies of patients with a 
range of OIs have shown similar associations [33–36] although one 
study found that KS-associated IRD was associated with a higher 
CD4 cell count at KS diagnosis [8]. Higher baseline HIV-1 viral 
load and a more rapid fall in viral load during ART have also been 
identified as risk factors [17,20,33,34,37–39].
Other risk factors
Incidence rates of paradoxical TB-IRD vary widely according 
to setting from 0% in a Tanzania study [40] to 45% in a French 
cohort [41]. In addition to the variables discussed earlier, other pos-
sible explanations for heterogeneity in risk are differences in preva-
lent strains of M. tuberculosis, genetic factors or study design issues 
(especially case definitions). No association with TB strain type 
was demonstrated in two relatively small studies [42,43]. Genetic 
studies have found polymorphisms in the TNF-a and IL-6 genes 
to be associated with mycobacterial IRD [44] and certain HLA 
polymorphisms to be associated with CMV IRD [45]. One study 
in the USA also found TB-IRD to be associated with black race 
[16]. Others have hypothesized that vitamin D deficiency may play 
a role in the development of IRD since 1,25-dihydroxyvitamin D 
has a role in pathogen clearance, the inflammatory response and 
macrophage activation [46]. 
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Figure 2. Relationship between the proportion of patients with TB and CD4 cell 
counts <100 cells/µl who developed immune reconstitution disease and the 
timing of initiation of antiretroviral therapy during TB treatment. For the periods 
0–30, 31–60, 61–90, 91–120 and >120 days, the proportions of patients with IRD were 
13/16, 9/30, 3/21 3/35 and 1/59, respectively.   
ART: Antiretroviral therapy; IRD: Immune reconstitution disease.  
Data taken from [4].
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Most studies have shown no association between specific 
classes of antiretroviral drugs and risk of IRD. However, one 
study showed that patients receiving non-nucleoside reverse 
transcriptase inhibitors and protease inhibitors (PIs) together 
were more likely to develop KS-associated IRD [8]. One other 
study found ritonavir-boosted PIs to be associated with IRD [33]. 
Immunopathogenesis
Immune reconstitution disease most commonly occurs during 
the early, most rapid phase of immune recovery and is character-
ized by exaggerated inflammatory responses. However, the precise 
mechanisms underlying the immunopathology of IRD are incom-
pletely understood and may differ according to the OI involved. 
For example, mycobacterial and fungal IRD are characterized by 
granulomatous inflammation whereas CD8+ T-lymphocyte infil-
trates predominate in IRD associated with viral infections [2,47]. 
Here, we review data concerning a range of different OIs. A sum-
mary of the key factors involved in pathogenesis is shown in Figure 3. 
Our understanding of these mechanisms is important for the devel-
opment of immunomodulatory pharmacological interventions for 
treatment and prevention of IRD.
Mycobacterial immune reconstitution disease
The first reports of mycobacterial IRD in the early 1990s were 
in patients who developed localized forms of Mycobacterium 
avium complex disease, such as focal lymphadenitis, after start-
ing zidovudine monotherapy [48]. These unusual presentations 
and subsequent reports of TB-IRD were associated with a switch 
in skin test responses to mycobacterial antigens from anergic to 
strongly positive, implicating recovery of delayed-type hyper-
sensitivity responses [38,48]. This notion was supported by the 
observation that these clinical phenom-
ena were typically, though not invariably, 
associated with increases in peripheral 
blood CD4 cell counts. In the minority 
of patients in whom no such increases 
are seen [12,38], early immune recovery 
could be associated with accumulation of 
pathogen-specific CD4 cells at the tissue 
site of disease without being reflected in 
peripheral blood. 
Cytokine release assays have been used to 
explore the association between increases in 
mycobacterial-specific T cells in peripheral 
blood and paradoxical TB-IRD [41,49–53]. 
Bourgarit et al. reported that TB-IRD was 
associated with large expansions of purified 
protein derivative (PPD)-specific T cells 
producing IFN- g [49] and similar findings 
have been reproduced in other studies [50,52]. 
Bourgarit et al. also recently reported that 
these PPD-specific T cells are highly acti-
vated, multifunctional (IFN-g+ TNF-a+ 
IL2-) cells of the CD4+ effector memory 
phenotype [41]. TB-IRD patients were also 
found to have high levels of gd T cells, which had reduced expres-
sion of killer Ig-related receptor at baseline and at the time of 
TB-IRD, suggesting a possible deficiency in immune regulation 
and a role in pathogenesis [41].
In contrast to the findings of Bourgarit et al., a cross-sectional 
study conducted in South Africa showed that while TB-IRD 
patients had greater T-cell expansions in response to a range of 
mycobacterial antigens compared with controls, responses in both 
cases and controls were heterogeneous [51]. Moreover, in longitu-
dinal analyses, T-cell expansions and contractions were observed 
in both groups, raising the question as to whether cell expansions 
were the actual cause of TB-IRD or an epi-phenomenon [51]. 
It has also been suggested that paradoxical TB-IRD is precipi-
tated by a ‘cytokine storm’ [54]. TB-IRD has been shown to be 
associated with elevated concentrations of a range of Th1 and 
inflammatory cytokines and chemokines, but not Th2 cyto-
kines [49]. In a South African study, in vitro re-stimulation of 
peripheral blood mononuclear cells with mycobacterial antigens 
resulted in markedly increased production of a broad range of 
cytokines and chemokines in TB-IRD cases compared with 
controls [55]. However, TNF-a, IFN-g and IL-6 were the most 
consistently elevated cytokines and these were also present 
in markedly increased concentrations in unstimulated serum 
samples [55]. 
It has been hypothesized that paradoxical TB-IRD may reflect 
a relative delay in recovery of regulatory T-cell numbers and func-
tion [54,56]. Two studies found no such deficiency [51,52], however, 
and Seddiki et al. demonstrated expansions of CD127lo Foxp3+ 
CD25+ T-regulatory cells and a higher ratio of T-regulatory: effec-
tor/memory subsets in TB-IRD patients [57]. However, in this 
study, in vitro suppression assays demonstrated reduced functional 
Greater expansions of
pathogen-specific activated
effector T lymphocytes
• CD8+ T lymphocytes may play 
  the major role in viral IRD
• γδ T cells may play a role in
  TB IRD
Delayed recovery of 
T-regulatory cell numbers†
and/or function
Clinical presentation with 
heightened inflammatory 
features (systemic and/or
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Figure 3. The immunopathogenesis of immune reconstitution disease: 
mechanisms that have been hypothesized and studied. 
†No study has demonstrated deficient numbers of T-regulatory cells in IRD patients, 
although studies have suggested impaired function.  
ART: Antiretroviral therapy; IRD: Immune reconstitution disease.
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capacity and reduced IL-10 secretion from suppressor cells in 
TB-IRD patients. This suggested that although T-regulatory 
cell numbers were increased, their ability to downregulate aber-
rant immune responses was compromised. Another study of two 
patients with mycobacterial IRD demonstrated impaired IL-10 
and increased IFN-g production [56]. Thus, while no deficiency in 
T-regulatory cell numbers in mycobacterial IRD has been shown, 
data suggest there may be functional impairment that contributes 
to dysregulated inflammation.
The role of the innate immune system in IRD is unknown but 
it has been hypothesized that macrophages may be important [58]. 
A fatal case of unmasking pulmonary TB-IRD was found to have 
bronchiolitis obliterans organizing pneumonia at autopsy with an 
infiltrate consisting predominantly of macrophages [59]. Oliver 
et al. demonstrated that TB-IRD was associated with higher con-
centrations of CXCL10 and IL-18, also suggesting that innate 
immune responses contribute to pathogenesis [60]. Neutrophils are 
likely involved given that suppurative lymphadenitis and abscess 
formation are frequent features of TB-IRD.
Cryptococcal IRD
Higher cryptococcal antigen titer in CSF [20] and lower levels of 
inflammation at diagnosis [61] have been associated with develop-
ment of IRD. This suggests that poorly controlled fungal replication 
prior to ART related to poor immune response may establish the 
conditions for subsequent IRD. Glucuronoxylomannan, a major 
constituent of the capsular wall of cryptococcus, has immuno-
modulatory effects and may contribute to establishing these con-
ditions [62]. Cryptococcal antigen persists in the CNS for months 
despite antifungal treatment, providing a potent antigenic stimulus. 
Cryptococcal IRD has been associated with an exacerbation 
of proinflammatory responses in CSF. In patients who developed 
cryptococcal IRD, CSF leukocyte counts and concentrations of 
IFN-g, TNF-a, GCSF, VEGF and eotaxin have been reported 
to be higher at time of IRD compared with at the time of initial 
diagnosis of cryptococcosis [20,61]. However, this differs from the 
findings of a South African study [22].
Immune reconstitution disease associated with other 
opportunistic diseases
Kaposi’s sarcoma IRD is characterized by the enlargement of 
lesions, inflammation or edema, and emergence of new lesions 
during ART. Proinflammatory cytokine and chemokine produc-
tion that increase during ART may upregulate expression of factors 
inducing angioproliferation and tumorigenesis in such patients 
[31,63,64]. However, KS IRD lesions may also spontaneously regress 
following development of IRD [65], suggesting that this may reflect 
the early stage of an ultimately beneficial immune response.
CMV immune recovery uveitis (IRU) is characterized by 
inflammatory cell infiltrates in the posterior chamber (vitritis), 
macular edema and epiretinal membrane formation [66]. Cells 
that may be involved include natural killer cells [62] and cyto-
toxic CD8+ T lymphocytes [67]. One study showed that CMV 
IRU could be distinguished from CMV retinitis that occurs in 
patients not on ART by presence of IL-12, lower levels of IL-6, 
and absence of detectable CMV replication in aqueous vitreal 
fluid [66]. CMV IRU is associated with an increase in plasma 
CMV-specific IgG [68].
Prevention: clinical interventions
In light of what is known of the risk factors and immunopathogenesis 
of IRD, it follows that a range of different interventions may reduce 
the risk and severity of unmasking and paradoxical forms of IRD. 
These include the initiation of ART much earlier in the course of 
HIV progression, preventive therapy for OIs prior to ART eligibil-
ity, pre-ART screening for OIs, use of optimized treatment for OIs, 
adjustment of the timing of starting ART during OI treatments, and 
immunosuppressive and immunomodulatory therapies.
Global interventions to prevent both unmasking & 
paradoxical IRD
Timing of ART initiation during HIV progression
Early ART is arguably the most important strategy to reduce 
the risk of both OIs and associated risks of unmasking and 
paradoxical IRD. There is substantial geographical variation 
in baseline CD4 cell counts. In patients (n = 24,444) starting 
ART in Europe between 1997 and 2006, the median CD4 cell 
count was 230 cells/µl [69]. By contrast, 18 cohorts containing 
39,536 patients in sub-Saharan Africa had median CD4 cell 
counts typically in the range of 100–150 cells/µl [70], similar to 
cohorts in Latin America and the Caribbean [71]. However, the 
median CD4 cell count among 58,000 patients starting ART in 
Thailand between 2000 and 2005 was just 41 cells/µl [72]. 
ART guidelines now recommend earlier initiation of ART. 
WHO guidelines in 2002 initially only recommended ART for 
patients with WHO stage four disease (AIDS) and those with 
CD4 cell counts <200 cells/µl [201]. Current guidelines now rec-
ommend ART for all patients with CD4 cell counts <350 cells/µl 
and for all patients with WHO stage three or four disease (which 
includes all TB patients) regardless of CD4 cell counts [202]. In 
many high-income settings, it is recommended to start ART even 
earlier, including patients with CD4 cell counts between 350 and 
500 cells/µl in the USA, for example [73].
Some evidence indicates that baseline CD4 counts in cohorts in 
sub-Saharan Africa and South America have increased over time 
during ART scale-up [74–76]. Despite such trends, late presentation 
is likely to remain an issue worldwide, especially in resource-
limited settings [77]. Here, a large majority of patients still have 
baseline counts <200 cells/µl and such patients are therefore at 
substantial risk of opportunistic disease and potential IRD. 
Prevention of opportunistic infections pre-ART 
Pre-ART care provides an opportunity to prevent OIs, includ-
ing TB and cryptococcal disease, thereby reducing the risk of 
associated IRD. 
Prevention of TB
Isoniazid-preventive therapy (IPT) reduces the risk of TB by 33% 
overall and by 64% (95% CI: 39–78%) among individuals who 
have a positive tuberculin skin test (TST); no benefit is derived by 
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those with a negative TST [78]. Patients who sequentially receive 
IPT and then ART may derive an additive TB preventive effect 
as these two interventions have differing and complementary 
mechanisms of action [79–81]. 
Uptake of IPT among HIV-infected individuals worldwide 
has been extremely low, being provided for an estimated 0.2% 
of eligible individuals worldwide in 2008 [203]. One key hurdle 
to scaling up this intervention has been the difficulty in reliably 
excluding active TB disease prior to IPT. The WHO previously 
recommended a cough duration of 2–3 weeks as a symptom screen 
for TB [82,204]. This is now recognized as inadequate for HIV-
associated TB, with the sensitivity frequently being found to be 
less than 50% in this patient group [83–85]. 
Screening tools that combine multiple symptoms have much 
higher sensitivity, albeit with low specificity. A meta-ana lysis of 
nearly 10,000 HIV-infected patients actively screened for TB has 
been conducted to derive a high-sensitivity symptom screening algo-
rithm [86]. The optimum algorithm identifies patients who have one 
or more of four common symptoms (current cough, night sweats, 
weight loss or fever) with a sensitivity of 79% and a specificity of 
50%. For individuals who are not yet eligible for ART and who 
have a TB prevalence less than 10%, the negative predictive value 
of this screening tool is very high and is regarded as sufficient to 
identify those with a very low probability of TB who can then start 
IPT [83]. Use of this algorithm may help increase uptake of IPT.
Prevention of cryptococcal disease
Routine primary fluconazole prophylaxis in both developed and 
developing world settings has been shown to reduce the num-
ber of cases of cryptococcal meningitis, yet it has not shown a 
consistent survival benefit [87]. Large numbers of patients require 
long-term medication, concerns exist around the development of 
drug resistance and cost–effectiveness analyses are unfavorable in 
many settings [88–90]. Thus, few national programs recommend 
this although the benefit may vary substantially between countries. 
A study from Cambodia reported that routine use of fluconazole 
prophylaxis during ART was associated with a 50% reduction in 
adjusted hazards of death among those with baseline CD4 cell 
counts of <100 cells/µl [91]. Routine fluconazole prophylaxis given 
in this way has not been shown to select for fluconazole resistance 
in cryptococcal isolates [92] although there is an association with 
development of fluconazole-resistant Candida [93]. 
In a large community-based placebo-controlled trial of fluconazole 
prophylaxis administered three-times weekly in Uganda, a signifi-
cantly reduced risk of cryptococcal disease was observed. However, 
overall disease rates were very low because of the exclusion of patients 
found to have a positive serum cryptococcal antigen on screening 
at baseline [94]. Here, an approach of screening for cryptococcal 
antigenemia prior to starting ART and using targeted pre-emptive 
therapy may be a more cost-effective strategy, as discussed later [95,96]. 
In patients who have been treated for cryptococcal meningitis, 
secondary prophylaxis with fluconazole is very important. Lack 
of provision or poor patient adherence with such treatment results 
in high rates of secondary cases in South Africa [97] and high 
 associated mortality risk during early ART [98,99].
Interventions to prevent unmasking IRD
Unmasking IRD arises in patients with undiagnosed OIs pres-
ent at the time of ART initiation. Systematic screening for OIs 
represents the key means to prevent this.
Screening for TB pre-ART
There is a very strong rationale for screening and rapid TB 
diagnosis among patients accessing ART services to reduce 
morbidity, mortality and nosocomial transmission. Early diag-
nosis and rapid initiation of TB treatment are also likely to 
reduce risks of unmasking and paradoxical TB-IRD by lim-
iting the extent of disease and mycobacterial antigen load. 
In contrast to unmasking cryptococcal IRD, the majority 
of unmasking TB disease has a clinically unremarkable pre-
sentation (therefore simply referred to as ‘unmasking TB’). 
However, a small subset of such cases present with overtly 
hyper-inflammatory features that might truly be considered 
true ‘unmasking TB-IRD’ [100] and such presentations are 
occasionally life-threatening and fatal [59,101]. In addition to 
patients referred to ART programs with known TB diagnoses, 
there is a large burden of undiagnosed TB among the remain-
ing patients. The proportion detected is likely to vary greatly 
depending on the prevailing TB burden, the degree of immuno-
deficiency and the rigor with which patients are screened [102]. 
The prevalence of TB is established most accurately when 
all patients are screened for TB regardless of the presence or 
absence of symptoms and when high-sensitivity investigations, 
such as automated liquid culture, are used [85,102]. In two such 
studies of South African cohorts, patients had median CD4 
cell counts of approximately 100 cells/µl and pulmonary TB 
was diagnosed in 19% of patients in Durban [103] and 25% of 
patients in Cape Town, South Africa [29] when sputum samples 
from all patients were examined using automated liquid cul-
ture. Prevalence was substantially higher among the subset of 
patients with CD4 cell counts <100 cells/µl [29].
In the Cape Town cohort, approximately 40% of cases of TB 
presenting during the first 4 months of ART were estimated to be 
due to unmasking TB [104]. Consistent with this, efficient baseline 
screening in the same cohort was associated with a substantial 
reduction in the incidence of TB (approximately halved) during 
the initial months of ART [105]. In effect, this high-sensitivity 
routine screening substantially reduced the risk of unmasking 
TB during early ART and this may well also minimize the risk 
of the more severe cases of unmasking IRD [59,101].
The great challenge of screening for TB in this patient popula-
tion is that a large majority of the disease is sputum smear nega-
tive. Owing to the very low numbers of mycobacteria in sputum of 
many such patients, the time to positive culture is also prolonged, 
with a mean of over 3 weeks in one study in Cape Town [29]. Newer 
diagnostics are urgently required to provide simpler and more rapid 
diagnosis. A simple, commercially available ELISA is able to detect 
LAM excreted in the urine of patients with TB. Despite disappointing 
performance in non-HIV-infected patients [106], moderate sensitivity 
and high specificity has been observed in HIV-infected patients 
in South Africa [29,30,107]. 
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In each of these studies of HIV-infected patients [29,30,107], 
the sensitivity of the LAM assay exceeded that of sputum smear 
microscopy and was highest in patients with the lowest CD4 
cell counts. In ambulatory patients screened prior to ART, the 
sensitivity of the assay was 67% in those with CD4 cell counts 
<50 cells/µl and specificity was excellent [29]. LAM antigenuria 
at baseline was also predictive of the development of paradoxical 
TB-IRD [29] although larger studies are needed to evaluate this 
association further. A simplified lateral flow version (‘dip-stick’) 
of this urine LAM assay is currently being evaluated [106]. If the 
sensitivity and specificity of this assay is at least comparable to 
the ELISA, it could be used as a simple and cheap point-of-care 
test incorporated within a diagnostic screening algorithm for 
 out-patients accessing ART or for HIV-infected in-patients. 
Nucleic acid amplification tests (NAATs) represent the most 
promising development for rapid diagnosis of TB and rapid drug 
susceptibility testing [108]. Progress has been made in develop-
ing simplified versions of these tests with higher sensitivity for 
smear-negative disease. The most important of these to date is a 
sensitive and specific fully automated and commercially available 
NAAT assay, which has been developed for use outside reference 
laboratory centers [109,110]. The Xpert MTB/RIF Assay (Cepheid, 
Sunnyvale, CA, USA) uses real-time PCR technology to detect 
M. tuberculosis and the rpoB rifampicin resistance mutation. The 
cartridge-based system dispenses with the need for prior sputum 
processing, requires minimal laboratory expertise and results are 
available in less than 2 h, providing a specific TB diagnosis and 
a rapid assessment of rifampicin resistance. A large multicountry 
evaluation found excellent performance characteristics, including 
sensitivities of 72.5, 85.1 and 90.2% for sputum smear-negative 
disease when processing one, two or three sputum specimens, 
respectively [110]. This assay requires evaluation for TB screening 
in ART programs; in this setting it may be stretched to the limits 
of its diagnostic sensitivity [111].
In a study among patients initiating ART in Cambodia, posi-
tive IFN-g-release assays (IGRAs) were found to be strongly 
predictive of unmasking TB [50], presumably due to association 
with un diagnosed TB at baseline. The study did not specify how 
patients were screened for TB pre-ART and what the incremental 
value of IGRAs was above other diagnostic tests. However, the 
inability of such assays to distinguish between active and latent 
disease limits their utility, especially in high TB burden settings. 
Screening for cryptococcal disease pre-ART
The clinical course of patients with asymptomatic crypto coccal 
antigenemia remains poorly defined since all such patients 
who are identified typically receive treatment. However, if left 
untreated, clinical disease may develop as fungal burden increases 
in the context of persisting immunodeficiency [88]. Alternatively, 
if ART is commenced, rapid restoration of pathogen-specific 
immune responses may cause unmasking of subclinical disease. 
Such unmasking cryptococcal disease has a poor prognosis and 
contributes substantially to early mortality in ART programs in 
Africa [70,95,99]. Cryptococcal antigen screening pre-ART,  however, 
offers a potential solution.
Two retrospective studies from Africa have found that crypto-
coccal antigen detected in stored serum samples obtained pre-
ART was an independent predictor of mortality [95,112]. In the 
South African study, the prevalence of antigenemia was 13% 
among patients with CD4 cell counts <100 cells/µl and an 
antigen titer of ≥1:8 was 100% sensitive and 96% specific for 
predicting development of cryptococcal meningitis during the 
first year of ART [95]. Use of this as a screening test pre-ART 
might permit implementation of a targeted pre-emptive treat-
ment strategy, preventing most, if not all, cases of unmasking 
cryptococcal disease during ART. Such a screening strategy 
was evaluated as being a highly cost-effective intervention in 
Uganda [96]. Simplified point-of-care methods for antigen test-
ing are needed together with evaluation of the impact of pre-
emptive therapy for those found to be antigen positive. The 
optimal management strategy for such patients remains to be 
defined.
Screening for CMV ophthalmic disease
Development of immune recovery uveitis during ART in patients 
with CMV retinitis at baseline may result in visual loss [7,113,114]. 
Screening for CMV retinitis is therefore of great importance, 
especially among treatment-naive patients with very low CD4 
cell counts (<100 cells/µl). Ideally, retinal examination should 
form part of the normal standard of care of all HIV-infected 
individuals. The gold standard for detection of CMV retinitis is 
retinal examination through a dilated pupil by a skilled exam-
iner (usually a trained ophthalmologist), using a binocular indi-
rect ophthalmoscope and condensing lens [115]. However, this is 
impractical in many settings.
Approaches to simplify screening might include the initial use 
of symptom screening. However, the predictive value of symp-
tom screening is highly variable with the proportion of patients 
with newly diagnosed CMV retinitis who have symptoms vary-
ing geographically, being higher in the USA and UK than in 
nonindustrialized countries. In India, for example, symptom 
screening had a sensitivity of just 7.7% and a positive predictive 
value of 18% [116]. Clearly, in many settings, ocular examina-
tion cannot be the sole domain of the ophthalmologist and 
non-ophthalmic personnel require training in ophthalmoscopy. 
Alternative approaches might be to use fundus cameras that 
could be systematically reviewed by trained personnel to select 
those cases requiring specialist review.
It is important to note that despite diagnosing and appropriately 
treating CMV retinitis prior to ART, a proportion of patients 
will still develop CMV immune recovery uveitis as a paradoxical 
IRD. However, limiting the extent of CMV retinitis by earlier 
treatment may reduce this risk.
Interventions to prevent paradoxical IRD
The risk and severity of paradoxical IRD are likely to be strongly 
associated with the residual antigen burden present at the time of 
rapid immune recovery following ART initiation. This might be 
reduced by effective OI treatment and by adjusting the  timing 
of ART.
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Effective treatment of OIs 
The amount of residual OI antigen present at the time ART is 
started is a function not only of the preceding duration of OI 
treatment but also of the efficacy of that treatment. In a large 
case series of TB-IRD in Cape Town, undiagnosed rifampicin-
resistant TB (mostly multidrug resistant) in patients receiving 
first-line TB treatment was detected in 10.1% of cases and it 
is possible that reduced clearance of mycobacterial antigen in 
such patients predisposed to IRD [117]. Much more widespread 
 availability of routine TB drug susceptibility testing is needed. 
Optimal care for patients with cryptococcal meningitis includes 
the use of intravenous amphotericin B – a fungicidal drug that 
leads to rapid clearance of the organism from the CSF when mea-
sured by serial quantitative CSF cultures [118,119]. However, in 
many resource-limited settings, the standard of care for initial 
treatment of cryptococcal meningitis is oral fluconazole provided 
by the Pfizer free access program. Fluconazole, however, is essen-
tially a fungistatic drug and high organism load persists in CSF 
during the first 2 weeks of fluconazole treatment [120]. This may 
in turn predispose to cryptoccal IRD, which may possibly be 
one among several factors contributing to the extremely high 
mortality observed among patients starting ART within 72 h of 
treatment for cryptococcal meningitis using oral fluconazole in a 
randomized controlled trial in Zimbabwe [121–123]. 
There is currently no other treatment available for PML other 
than ART, which triggers IRD in 16.7% of cases [11]. However, 
in vitro data and case reports suggest that the antimalarial drug 
mefloquine may have efficacy [124,125] and a Phase II multicenter 
clinical trial is underway [205].
Timing of ART during treatment of OIs
Risk of paradoxical IRD could theoretically be substantially 
reduced simply by deferral of ART initiation as suggested by 
Figure 2. However, observational studies have also shown that even 
short delays in the initiation of ART may be associated with sub-
stantial all-cause mortality risk, especially in resource-limited 
settings [98,126]. Risk of IRD and associated consequences is just 
one issue among a range of competing factors favoring either early 
or delayed initiation of ART during OI treatment [127]. Additional 
factors include the risks of drug co-toxicity, pharmacokinetic drug 
interactions, pill burden, treatment tolerability and overall risk of 
further morbidity and mortality.
Data on timing of ART in patients with OIs are now avail-
able from five randomized controlled trials in which mortality was 
included within the primary outcome (Table 2) [127]. The conclusions 
derived from these studies appear to differ according to whether or not 
the OI involves the CNS. A study of patients with acute OIs excluding 
TB (a multicenter trial that was largely based in the USA) [128] and two 
other studies of patients with TB in South Africa [19] and Cambodia 
[18] all showed an overall substantial mortality reduction among 
patients randomized to the earlier treatment arms (Figure 3). In the 
two studies of patients with TB, substantial mortality reduction 
was observed despite the approximately two- to threefold greater 
risk of IRD in the early treatment groups (Table 2) [18,19]. However, 
the study by Zolopa et al. of non-TB OIs did not find timing of 
ART to be associated with risk of IRD [37], but this may largely 
reflect the fact that most OIs represented were Pneumocystis jiro­
vecii pneumonia and acute bacterial infections, neither of which is 
associated with substantial risk of IRD.
In the study from Zimbabwe, patients with cryptococcal men-
ingitis receiving initial fluconazole therapy and no per-protocol 
therapeutic interventions to control CSF pressure had much higher 
mortality when randomized to start ART within 72 h of antifun-
gal treatment compared with starting after 10 weeks [121]. From 
clinical evaluation, the causes of death were ascribed largely to 
complications of cryptococcal meningitis, but clinical or post-
mortem data on IRD were lacking. In contrast to these data, 
the subset of patients with cryptococcal meningitis treated with 
amphotericin in the study by Zolopa et al., a strong trend towards 
lower risk of progression to AIDS and death among those receiving 
earlier ART was observed [128]. 
A study of patients with TB meningitis in Cambodia random-
ized to start ART immediately or after 2 months of TB treatment 
did not differ with regards to survival [129] but overall IRD events 
were not specifically reported (Table 2). In both studies of CNS OIs, 
it might be hypothesized that the consequences of IRD within the 
vital structures of the CNS confined within cranial cavity may 
be far worse than for IRD affecting structures outside the CNS 
[10]. In this case, risks and consequences of IRD may off-set or 
even outweigh the mortality benefit that is otherwise derived by 
 HIV-infected patients receiving early ART [127]. 
In summary, risk of paradoxical IRD is just one factor in 
a complex clinical scenario that affects the optimal timing of 
ART during OIs. However, the overall mortality risk is the 
overriding determinant and this may differ for intra-cranial and 
extra-cranial OIs and according to the efficacy of the treatment 
received for the OI. The most recent revision of the WHO ART 
guidelines recommend that ART be started as soon as possible 
within 2–8 weeks for all patients with HIV-associated TB, but 
no specific recommendations were made with regard to TB men-
ingitis or other OIs [202]. In light of these recommendations, 
it is clear that paradoxical TB-IRD will remain an important 
clinical issue and that strategies other than adjusting the timing 
of ART initiation will need to be sought in efforts to prevent 
this complication.
Prevention: pharmacological interventions
From the observations that the immunopathogenesis of IRD is 
associated with marked expansion of T lymphocytes, a marked 
proinflammatory cytokine drive and lack of regulatory immune 
function (Figure 3), it is logical to conclude that immunosuppressive 
and immunomodulatory therapies may be beneficial with regards 
to the treatment and prevention of IRD. 
Preventing complications of IRD
Case reports and case series describe a range of pharmacologi-
cal interventions used in IRD case management, including oral 
corticosteroids, NSAIDs, thalidomide and leukotriene receptor 
antagonists [3,130,131]. Other immunomodulatory agents such as 
TNF-a inhibitors have also been suggested for use. 
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Only one study has formally assessed an intervention using a ran-
domized controlled trial. In a study in Cape Town, South Africa, 
patients with moderately severe, non-life-threatening TB-IRD 
were randomized to receive either 4 weeks of oral corticosteroids 
or placebo [131]. Prednisone was given for 2 weeks at a dose of 
1.5 mg/kg per day for 2 weeks followed by 0.75 mg/kg per day 
for 2 weeks. The composite primary endpoint was days of hos-
pitalization and out-patient therapeutic procedures, the latter of 
which were counted as 1 day of hospitalization. Those receiving 
prednisone had a lower median number of days of hospitalization 
(0 vs 3 days; p = 0.04) and significantly greater improvements in 
symptoms, Karnofsky score and quality of life after 2 and 4 weeks 
despite a higher risk of nonsevere OI [131]. This study therefore 
provided important evidence of the benefit of oral corticosteroids 
for moderately severe IRD. 
It would be unethical to perform such a randomized trial 
among those with life-threatening manifestations of TB-IRD, 
but the data from the trial by Meintjes et al. clearly suggest their 
likely important role in such patients [131]. This includes patients 
with TB involving the CNS in whom coadministration of corti-
costeroids is widely regarded as standard of care [132]. Optimum 
case management of other forms of IRD, especially that compli-
cating cryptococcal disease, remains undefined. Specifically, the 
benefits of corticosteroids and repeated CSF lumbar draining to 
manage raised intracranial pressure are unknown. Use of other 
anti-inflammatory agents at present remains anecdotal.
Prevention of IRD
No clinical trials of pharmacological agents to prevent IRD 
have been completed. We are aware of just two clinical trials 
involving use of maraviroc and a NSAID. Statins, vitamin D and 
corticosteroids have also been suggested as other possible IRD 
prevention strategies. 
Maraviroc is a CCR5 chemokine receptor antagonist that not 
only blocks the uptake of R5-tropic HIV into CD4 cells but also 
has immunomodulatory properties [133], possibly by interfering 
with leukocyte recruitment to sites of inflammation through 
CCR5 blockade [134]. Maraviroc was used in the treatment of 
one patient with PML IRD and a surprisingly rapid clinical 
response was reported [135]. In the CADIRIS trial [206], patients 
in South Africa and Mexico starting ART are being random-
ized to receive maraviroc or placebo in addition to standard 
triple-drug ART. The primary outcome is the incidence of all 
forms of IRD. 
Another planned trial in South Africa plans to assess the 
use of a NSAID in the prevention of paradoxical TB-IRD. 
Table 2. Randomized clinical trials of early versus deferred initiation of antiretroviral therapy during 
treatment for opportunistic infections.
Study (year), 
country
Opportunistic infection Details Main results IRIS events (%) Ref.
Early 
arm 
Deferred 
arm 
Zolopa (2009),
Multi-country
Pneumocystis jirovecii pneumonia 
(63%)
Serious bacterial infections (12%)
Cryptococcal meningitis (12%)
Miscellaneous (13%)
ART started within 
14 days (median 12 days) 
vs ART after completing 
OI treatment (median 
45 days) 
Early ART reduced 
risk of AIDS 
progression/death 
(OR:0.51; 95% CI: 
0.27–0.94)
5.7 8.5 [128]
Abdool Karim et al. 
(2010), South Africa
Smear-positive pulmonary TB ART started during first 
3 months of TB treatment 
vs after completion of  
TB treatment
CD4 count 0–500 cells/µl
Mortality reduced in 
early arm (HR: 0.44)
12.4 3.8 [19]
Blanc et al. (2010), 
Cambodia
Smear-positive pulmonary or 
extrapulmonary TB
ART started 2 weeks after 
starting TB treatment vs 
2 months
CD4 counts <200 cells/µl
Mortality higher in 
2-month arm 
Adjusted HR: 1.52
33 15 [18]
Torok et al. (2009), 
Vietnam
Tuberculous meningitis Immediate ART at start of 
TB treatment vs after 
2 months
No significant 
difference in 
mortality but more 
adverse events in 
immediate arm
Not assessed [129]
Makadzange et al. 
(2010), Zimbabwe
Cryptococcal meningitis ART started within 72 h 
of diagnosis vs after 
10 weeks
Patients treated with 
fluconazole
3-year cumulative 
mortality 88% in 
early arm vs 54% in 
delayed arm 
(p < 0.006) 
Adjusted HR: 2.85
Not assessed [121]
ART: Antiretroviral therapy; HR: Hazard ratio; IRIS: Immune reconstitution inflammatory syndrome; OI: Opportunistic infection; OR: Odds ratio.
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TB patients will be randomized to receive either meloxicam (a 
NSAID) or placebo in addition to standard TB treatment and 
ART [Nachega J, Pers. Comm.]. 
Vitamin D acts on diverse cell types, mediating pleiotropic 
effects on the immune system and modulating both the adap-
tive and innate immune responses [136]. Epidemiological studies 
have linked vitamin D deficiency to various immune-mediated 
disorders and a potential role in IRD has been proposed [46]. 
Similarly, in addition to their lipid-lowering properties, statins 
have anti-inflammatory properties and there is precedence for 
using these agents for autoimmune inflammatory disorders in an 
experimental model [137,138]. It has been proposed that statins and 
vitamin D may therefore also be of potential use in the treatment 
or prevention of IRD. 
Corticosteroids have also been suggested for potential use for 
preventing paradoxical IRD. Although effective in case manage-
ment [131], use in prevention does not appear well justified. Use of 
corticosteroids in HIV-infected people is associated with a range 
of adverse effects including reactivation of herpes virus infections, 
exacerbation of KS and precipitating other infections, includ-
ing strongyloidiasis [131,139–141]. Given that paradoxical TB-IRD 
develops in around one in five patients with a TB diagnosis prior 
to ART, it would mean that four out of five patients would be 
unnecessarily exposed to the adverse effects of corticosteroids. 
Moreover, the ACTG5164 trial of the optimum timing of ART 
during treatment for OIs excluding TB found no association 
between use of corticosteroids and risk of IRD [37]. We think 
that corticosteroids are best reserved for treatment of certain 
forms of IRD, with the exception of patients with TB involving 
the CNS in whom routine use of corticosteroids is regarded as 
standard of care [132]. However, our experience is that cases of 
TB-IRD involving the CNS may nevertheless occur despite use 
of corticosteroids.
Expert commentary & five-year view
Despite guidelines recommending earlier initiation of ART, late 
presentation with advanced HIV is likely to persist as an issue in 
a substantial proportion of patients, especially in resource-lim-
ited settings. This, in turn, will continue to fuel high rates of OIs 
and associated risks of IRD. Furthermore, several recent ran-
domized controlled trials have shown that survival is improved 
with earlier initiation of ART during treatment for OIs, despite 
the increased risk of IRD. Resulting shifts in recommendations 
for rapid initiation of ART during OIs will also continue to 
fuel rates of paradoxical IRD. Additional prevention strategies 
are needed.
Development of simple means to rapidly and reliably screen 
for key infections prior to ART such as TB and cryptococcosis 
is of paramount importance. While optimum screening for HIV-
associated TB in this patient population is heavily reliant upon 
mycobacterial culture, which is expensive, slow and unavailable 
in many settings, real progress is now being made in the devel-
opment of new near-patient technologies and point-of-care tests 
that will greatly simplify TB screening and early detection of 
drug-resistant disease. Similarly, subclinical cryptococcal dis-
ease can also be readily diagnosed by detection of cryptococcal 
antigen in serum and we anticipate that point-of-care tests to 
detect antigen in blood or urine will simplify this process further. 
Operational research will also develop simpler means to screen 
for CMV retinitis pre-ART.
Key issues
• Unmasking and paradoxical forms of immune reconstitution disease (IRD) remain an important cause of morbidity, and patients with 
cryptococcal IRD in particular have substantial mortality risk. 
• Risk factors for paradoxical IRD include early initiation of antiretroviral therapy (ART) during opportunistic infection (OI) treatment, high 
antigen load in those with advanced OIs, low baseline CD4 cell counts, high baseline viral load and rapid immunological and virological 
responses to ART.
• The immunopathogenesis of IRD remains incompletely defined but studies have shown associations with T-cell expansion, 
proinflammatory cytokine release and diminished regulatory T-cell activity.
• Key to prevention of unmasking and paradoxical IRD is diminishing the risk of OIs through early HIV diagnosis and initiation of ART at 
CD4 cell counts greater than 200 cells/µl.
• Unmasking TB may be prevented using isoniazid-preventive therapy and rigorous TB screening prior to ART using high-sensitivity TB 
diagnostics (such as liquid culture of sputum). 
• Unmasking cryptococcal IRD can be prevented by pre-ART screening for blood cryptococcal antigen and pre-emptive treatment. 
• Prevention of immune recovery uveitis associated with cytomegalovirus (CMV) requires careful screening for CMV retinitis among 
patients starting ART. Paradoxical CMV immune recovery uveitis may occur, however, despite treatment of CMV retinitis.
• Risk of paradoxical IRD in patients with cryptococcal meningitis is likely to be reduced by using amphotericin B (a fungicidal drug that 
rapidly clears the organism from the cerebrospinal fluid) rather than fluconazole (a fungistatic drug), which is standard of care in many 
resource-limited settings. 
• Risk of paradoxical IRD could be reduced by delaying initiation of ART during OI treatment. However, several randomized controlled 
trials now show the overall survival benefit of early ART (with the possible exception of OIs involving the CNS). Mortality reduction by 
early initiation of ART is the over-riding priority. 
• Morbidity associated with TB IRD may be reduced using adjunctive corticosteroid therapy in patients with moderately severe disease. 
Optimum management of cryptococcal IRD, however, remains undefined.
• Trials of the use of drugs with immunomodulatory properties are planned, including the use of maraviroc and nonsteroidal anti-
inflammatories. Others agents such as statins and vitamin D are also being considered. 
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Ongoing basic research will extend our understanding of the 
immunopathogenesis of IRD and may provide the rationale for 
new immunomodulatory interventions. Identification of tran-
scriptional or proteomic signatures associated with IRD may 
facilitate diagnosis, overall simplifying clinical management. A 
single randomized clinical trial of corticosteroids has demon-
strated reduced morbidity in patients with paradoxical TB-IRD, 
but additional data will arise from further clinical trials to prevent 
paradoxical IRD using a range of drugs with immunomodu-
latory properties but fewer adverse effects than corticosteroids. 
Currently, no evidence-based pharmacological strategy for the 
prevention of IRD can be recommended.
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